Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR: Adjuvant palbociclib plus endocrine therapy vs endocrine therapy alone in HR-positive/HER2-negative resected isolated locoregional recurrent breast cancer
2024-510776-20-00Phase 3Authorised
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Invasive disease-free survival (iDFS). Planned start Apr 2024; status: authorised.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-510776-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510776-20-00.